Abstract: An information processing apparatus according to an embodiment includes: a common data model management unit that manages information indicating a common data model corresponding to a plurality of modules in common; a unique data model management unit that manages information indicating a unique data model corresponding to at least one of the modules; and a common management unit that manages a version of a module corresponding to the common data model managed by the common data model management unit, a version of a module corresponding to the unique data model managed by the unique data model management unit, and a version of a module corresponding to a newly installed data model, and verifies compatibility of the versions.

Abstract: According to one embodiment, an image processing apparatus 1 includes one or more hardware processors configured to function as an acquisition unit 20A, a pseudo label estimation unit 20B, and a learning unit 20C. The acquisition unit 20A acquires unlabeled training data including an image to which a correct label of an attribute is unassigned. The pseudo-label estimation unit 20B estimates a pseudo-label, which is an estimation result of the attribute of the image of the unlabeled training data, based on an identification target region according to a type of the attribute to be identified by a first learning model 30 to be learned in the image of the unlabeled training data. The learning unit 20C learns the first learning model 30 identifying the attribute of the image by using first labeled training data with the pseudo-label being assigned to the image of the unlabeled training data.

Abstract: This stator core is a stator core for a rotating electric machine of an axial gap type and includes a body portion formed by a compaction-molded body of soft magnetic powder whose surfaces are coated with insulating films, wherein the body portion is provided with one or a plurality of through holes.

Abstract: In one embodiment, a semiconductor storage device includes a lower electrode layer, a lower insulator, an upper electrode layer and an upper insulator along a first direction. The device further includes a first insulator provided on a side of a second direction of the upper electrode layer, and a second insulator provided between the upper electrode layer and the lower/upper/first insulator. The device further includes a charge storage layer, a third insulator and a semiconductor layer sequentially provided on a side of the second direction of the first insulator. A side face of the first insulator on a side of the upper electrode layer has a convex shape, the charge storage layer includes a first portion having a first thickness, and a second portion having a second thickness less than the first thickness, and the first portion is in contact with the first insulator.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: The present invention aims to provide novel pharmaceutical use of compound A or a pharmaceutically acceptable salt thereof, or a monohydrate of compound A. The present invention relates to a therapeutic or prophylactic agent for chronic kidney diseases containing compound A or a pharmaceutically acceptable salt thereof, or a monohydrate of compound A as the active ingredient.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: A projection system includes an imaging unit, a projection unit, and a controller. The imaging unit captures an image of a subject to generate a first captured image. The projection unit projects a projection image corresponding to the first captured image onto the subject. The controller generates the projection image, causes the projection unit to project the projection image, and adjusts a positional relationship that brings a position in the first captured image and a position in the projection image into correspondence with each other. The controller causes the projection unit to project a marker image including a marker indicating a reference in the positional relationship, acquires a second captured image generated by the imaging unit capturing an image of the projected marker image, and adjusts the positional relationship, based on the marker in the marker image and the marker in the second captured image.

Abstract: A projection device includes an invisible image sensor, a projector, a visible image sensor, an imaging optical system, a light guide, and a light shield. The invisible image sensor captures an invisible light image of a subject. The projector projects a projection image based on the invisible light image onto the subject with visible light. The visible image sensor captures an image of the subject onto which the projection image is projected. The system includes a diaphragm. The light guide guides light to enter the system and light exited from the projector. The light shield is disposed at a space from the light guide. A diaphragm value is set so that a length difference between an optical length from a near point in a DOF of the system and an optical length from the light shield is longer than a front DOF from the subject.

Abstract: This camera apparatus is provided with: a camera head that is able to perform imaging based on visible light having entered a medical optical device from a target portion of a subject to whom a florescence agent has been administered in advance and imaging based on fluorescence having entered the medical optical device from the target portion; and an image processing unit that, after amplifying the intensity of a fluorescence image inputted from the camera head and increasing the contrast between a black part and a white part in the fluorescence image, executes nonlinear conversion processing for the amplified fluorescence image, superimposes the fluorescence image having undergone the nonlinear conversion processing onto a visible image obtained by the imaging based on visible light, and generates a superimposed image for being outputted to an output unit.

Abstract: A projection device includes an invisible image sensor, a projector, a visible image sensor, an imaging optical system, a light guide, and a light shield. The invisible image sensor captures an invisible light image of a subject. The projector projects a projection image based on the invisible light image onto the subject with visible light. The visible image sensor captures an image of the subject onto which the projection image is projected. The system includes a diaphragm. The light guide guides light to enter the system and light exited from the projector. The light shield is disposed at a space from the light guide. A diaphragm value is set so that a length difference between an optical length from a near point in a DOF of the system and an optical length from the light shield is longer than a front DOF from the subject.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: An expansion tank, while maintaining gas-liquid separation performance of coolant circulating through an engine cooling apparatus, can absorb pressure variations occurring with volume change of the coolant even when an excessive amount of coolant is supplied. A bulkhead 42 partitions an expansion tank 30 into separate chambers R1 to R6 that communicate with each other via a first communication hole 44 positioned lower than a FULL line. The separate chambers R4 to R6 that constitute a separate chamber group X communicate with each other via a third communication hole 45a positioned higher than the FULL line. The separate chambers R1 to R3 that constitute a separate chamber group Y communicate with each other via a fourth communication hole 45b positioned higher than the FULL line. The separate chamber R1 and the separate chamber R4 communicate with each other via a second communication hole 45c disposed at the height of the FULL line.

Abstract: A visible light projection device includes a detecting unit that detects a first region emitting non-visible light, a projecting unit that performs projection using visible light onto a second region including the detected first region, and a control unit that controls the projecting unit to perform projection with a color selected by an operator. When a first color is selected as a color of visible light projected by the projecting unit onto a region other than the first region, the control unit informs the operator of first options to allow a color of visible light projected onto the first region to be selected from the first options. When a second color different from the first color is selected, the control unit informs the operator of second options to allow a color of visible light projected onto the first region to be selectable from the second options.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: A visible light projection device includes a detecting unit that detects a first region emitting non-visible light, a projecting unit that performs projection using visible light onto a second region including the detected first region, and a control unit that controls the projecting unit to perform projection with a color selected by an operator. When a first color is selected as a color of visible light projected by the projecting unit onto a region other than the first region, the control unit informs the operator of first options to allow a color of visible light projected onto the first region to be selected from the first options . When a second color different from the first color is selected, the control unit informs the operator of second options to allow a color of visible light projected onto the first region to be selectable from the second options.